Quantcast

Latest Cancer treatments Stories

2014-02-20 12:28:45

PHILADELPHIA, Feb. 20, 2014 /PRNewswire/ -- MS -- According to a new report from the World Health Organization, cancer cases are expected to surge by 20 percent over the next two decades. The World Cancer Report, produced by the WHO's specialized cancer agency, predicts that new cancer cases will rise from 14 million annually in 2012 to 22 million within 20 years, leaving millions more to cope with the disease and the often debilitating and painful side effects of treatment plans that...

2014-02-13 04:20:48

Pierre Fabre are thus reinforcing their oncology portfolio which already enjoys a combination of chemotherapies, monoclonal antibodies and immuno-conjugates assets at various development phases CASTRES, France and BANGALORE, India, February 13, 2014 /PRNewswire/ -- Pierre Fabre, the third largest French pharmaceutical company, and Aurigene, a leading biotech company based in India, today announced that the two companies have entered into a collaborative license, development and...

Children In The EU Denied Cancer Treatments Due To Regulations
2014-02-11 14:45:11

Lee Rannals for redOrbit.com - Your Universe Online European Union (EU) regulations are causing children with cancer to go without treatments, according to the Institute of Cancer Research (ICR). Leading cancer experts said that EU rules are causing some children with cancer to be denied potentially life-saving drugs because the guidelines only allow companies to trial some drugs only in adults. The experts believe that changes to these rules could allow children access to high...

2014-02-11 12:26:43

Recurrent lung cancer responds to Integrative Immunotherapy SCOTTSDALE, Ariz., Feb. 11, 2014 /PRNewswire/ -- Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. To view the multimedia assets associated with this release, please visit...

2014-02-10 12:26:14

GOSSELIES, Belgium, February 10, 2014 /PRNewswire/ -- iTeos Therapeutics SA today announced the filing of the Company's first patent applications protecting proprietary inhibitors of the intracellular enzyme TDO2, which is expressed at high levels in specific cancers. iTeos Therapeutics has collaborated with Ludwig Cancer Research over the last year to identify small molecule inhibitors of the enzyme that display nanomolar potency, good selectivity, favorable pharmacokinetics...

2014-02-03 12:29:37

Co-inventors of ATM technology joining company as General Manager of the ATM Program, Scientific Advisory Panel member, respectively SYDNEY, Feb. 3, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen...

2014-01-30 12:28:09

AUSTIN, Texas, Jan. 30, 2014 /PRNewswire/ -- XBiotech announced today that its collaboration with the European Medicines Agency (EMA) has resulted in establishment of a regulatory path for Xilonix(TM) registration in the European Union for the treatment of colorectal cancer. XBiotech AG will soon launch its Phase III registration study in Europe to evaluate Xilonix in patients with treatment-resistant colorectal cancer. Cancer treatment centers in at least 6 countries will be involved...

2014-01-29 16:28:12

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5s2nhx/drug_delivery_in) has announced the addition a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/5s2nhx/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery remains a challenge in management of cancer. Approximately 12.5...

2014-01-29 13:16:56

A University of Colorado Cancer Center study published today in the International Journal of Radiation Oncology Biology and Physics shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease. Eliminating these pockets of resistant disease allows patients to continue treating the overall condition with crizotinib, leading to improved 2-year survival rates...

2014-01-27 08:27:57

Dr. Marnix Bosch To Describe DCVax-Direct Technology And Program BETHESDA, Md., Jan. 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will make a presentation concerning NW Bio's DCVax-Direct Phase I/II Trial for inoperable solid tumor cancers at Phacilitate's Washington...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related